DMP 696

Drug Profile

DMP 696

Alternative Names: SK 696

Latest Information Update: 15 Jan 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anxiolytics; Pyrazoles; Small molecules; Triazines
  • Mechanism of Action Corticotropin-releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders

Most Recent Events

  • 17 Feb 2006 No development reported - Preclinical for Anxiety disorders in USA (unspecified route)
  • 30 Jun 2003 A clinical study has been added to the Anxiety disorders pharmacodynamics section
  • 12 Jun 2003 Preclinical trials in Anxiety disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top